Julphar operates in more than 50 countries across the world and employs 2,144 people. The company recorded revenues of $311 million and assets worth $661 million in 2021. In December 2021, Julphar signed an exclusive license and production agreement with Quantum Genomics to produce and market Firibastat—an APA inhibitor prodrug—in the Middle East, Africa, CIS, and Turkey. Mohamed was previously CEO of ELKENDI and MSPHARMA Group for eight and seven years, respectively.